Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial
Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.
·1 source
